Ivermectin, Drugs Monitor, Page 3

(16 April 2020) Ivermectin- Use requires careful risk–benefit considerations

Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0271 Extreme due diligence and regulatory review are needed before testing ivermectin in severe disease for following 3 points, Neurotoxicity Concurrent use of antiretrovirals Doses required to reach… Continue reading

(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies

April 21, 2020

Ivermectin- inhibits the replication of SARS-CoV-2 in vitro https://www.sciencedirect.com/science/article/pii/S0166354220302011 Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activityin vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection… Continue reading "(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies"

Tag: Ivermectin

(16 April 2020) Ivermectin- Use requires careful risk–benefit considerations

(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies